We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.11 | -0.12% | 91.79 | 91.77 | 91.79 | 91.94 | 91.60 | 91.83 | 62,379 | 08:37:02 |
From May 2021 to May 2024
By Cecilia Butini
Sanofi SA said Monday that the coronavirus vaccine it is developing with GlaxoSmithKline PLC has achieved positive results in a Phase 2 trial, and that a global pivotal Phase 3 study is expected to start in the coming weeks.
The French pharmaceutical major said the vaccine showed strong rates of neutralizing antibody responses in all adult age groups that were part of the trial, reaching levels comparable to those generated by natural infection.
The upcoming Phase 3 trial is expected to enroll more than 35,000 adults from a broad range of countries, assessing the efficacy of two vaccine formulations that are set to include the Wuhan and South African variants.
The shot is expected to be approved in the fourth quarter of 2021, pending Phase 3 outcomes and regulatory reviews.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
May 17, 2021 02:05 ET (06:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
